Real-World Results of Aflibercept versus Ranibizumab for the Treatment of Exudative AMD Using a Fixed Regimen
المؤلفون المشاركون
Murta, Joaquim
Providência, Joana
Rodrigues, Tiago M.
Oliveira, Mariana
Bernardes, João
Marques, João Pedro
Silva, Rufino
المصدر
العدد
المجلد 2018، العدد 2018 (31 ديسمبر/كانون الأول 2018)، ص ص. 1-7، 7ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2018-06-06
دولة النشر
مصر
عدد الصفحات
7
التخصصات الرئيسية
الملخص EN
Intravitreal injections of antivascular endothelial growth factors have been considered a milestone in the treatment of neovascular age-related macular degeneration (nAMD).
However, the increasing incidence of AMD and the burden of visits and injections overcharge both the patient and the healthcare systems.
Real-world solutions depend on treatment protocols aimed at optimizing the number of clinical visits while guaranteeing good functional outcomes.
We performed a retrospective analysis of 72 eyes from 63 naïve patients diagnosed with nAMD that underwent a fixed intravitreal protocol consisting of bimonthly injections after a three-month loading dose, with either Aflibercept or Ranibizumab (no predefined criteria for treatment selection).
Best corrected visual acuity (BCVA) and optical coherence tomography were analyzed at baseline and during follow-up clinical visits (months 3, 6, 12, and 18).
From the included participants, 42 followed a fixed regimen with Aflibercept and 30 with Ranibizumab.
At the 12-month visit, there was not a statistically significant difference in the mean change of BCVA between the two groups (p=0.121); however, the mean difference in the central retinal thickness was significantly superior in the Aflibercept group (-142.2 versus -51.5, p=0.011).
The described fixed regimen seems to be efficient in the treatment of nAMD in a clinical practice setting.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Providência, Joana& Rodrigues, Tiago M.& Oliveira, Mariana& Bernardes, João& Marques, João Pedro& Murta, Joaquim…[et al.]. 2018. Real-World Results of Aflibercept versus Ranibizumab for the Treatment of Exudative AMD Using a Fixed Regimen. BioMed Research International،Vol. 2018, no. 2018, pp.1-7.
https://search.emarefa.net/detail/BIM-1129648
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Providência, Joana…[et al.]. Real-World Results of Aflibercept versus Ranibizumab for the Treatment of Exudative AMD Using a Fixed Regimen. BioMed Research International No. 2018 (2018), pp.1-7.
https://search.emarefa.net/detail/BIM-1129648
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Providência, Joana& Rodrigues, Tiago M.& Oliveira, Mariana& Bernardes, João& Marques, João Pedro& Murta, Joaquim…[et al.]. Real-World Results of Aflibercept versus Ranibizumab for the Treatment of Exudative AMD Using a Fixed Regimen. BioMed Research International. 2018. Vol. 2018, no. 2018, pp.1-7.
https://search.emarefa.net/detail/BIM-1129648
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1129648
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر